LightDark Log in Sign up

‹ Back to screener

GLENMARK.NS Glenmark Pharmaceuticals Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2025-08-21 ₹1940.90
2026-08-21 ₹2310.30
Change over window +19.03%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 48.9%
Trailing 20-day average 42.9%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 807816 395151 48.92%
2026-08-27 447011 200850 44.93%
2026-08-26 479931 179829 37.47%
2026-08-25 653245 278136 42.58%
2026-08-24 710023 308428 43.44%
2026-08-21 237421 79039 33.29%
2026-08-20 552157 217144 39.33%
2026-08-19 833583 352336 42.27%
2026-08-18 379551 259994 68.50%
2026-08-17 305189 151635 49.69%
2026-08-14 629081 329078 52.31%
2026-08-13 413167 192381 46.56%
2026-08-12 464575 140547 30.25%
2026-08-11 284670 119361 41.93%
2026-08-10 257787 93766 36.37%
2026-08-07 437610 179407 41.00%
2026-08-06 556267 227413 40.88%
2026-08-05 388492 140070 36.05%
2026-08-04 444946 224203 50.39%
2026-08-03 1307223 412334 31.54%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers GLENMARK.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
25 Sep 2023 Mr. Praveen D Kurkal Employees/Designated Employees Sell Market Sale 500 425510 0.00% XBRL
25 Sep 2023 Mr. Praveen D Kurkal Employees/Designated Employees Sell Market Sale 1000 852000 0.00% XBRL
25 Sep 2023 Mr. Praveen D Kurkal Employees/Designated Employees Sell Market Sale 1000 852000 0.00% XBRL
24 Nov 2021 Robin Pinto Promoter Group Buy Market Purchase 250 122548 0.18% XBRL
17 Nov 2021 SRIDHAR GORTHI Director Sell Market Sale 559 299447 0.00% XBRL
29 Sep 2021 AISHA LOUISE SALDANHA Immediate relative Sell Gift 10000 0 0.00% XBRL
29 Sep 2021 RAYNA MARIE SALDANHA Immediate relative Sell Gift 10000 0 0.00% XBRL
29 Sep 2021 NEHA SALDANHA Promoter Group Buy Gift 20000 0 0.00% XBRL
27 Sep 2021 Glenn Mario Saldanha Promoters Buy Market Purchase 9800 5027549 0.35% XBRL
23 Sep 2021 Cherylann Maria Pinto Promoters Buy Market Purchase 1950 1000087 0.27% XBRL
28 Jun 2021 Glenn Mario Saldanha Promoters Buy Market Purchase 7800 4992000 0.35% XBRL
24 Jun 2021 Glenn Mario Saldanha Promoters Buy Market Purchase 2800 1797197 0.34% XBRL
12 Jun 2021 Glenn Mario Saldanha Promoters Buy Market Purchase 7870 5011943 0.34% XBRL
16 Nov 2020 AISHA LOUISE SALDANHA Immediate relative Buy Market Purchase 10000 4877192 0.00% XBRL
16 Nov 2020 RAYNA MARIE SALDANHA Immediate relative Buy Market Purchase 10000 4877519 0.00% XBRL
29 Sep 2020 Robin Pinto Promoter Group Buy Market Purchase 750 372203 0.18% XBRL
28 Sep 2020 Robin Pinto Promoter Group Buy Market Purchase 250 112832 0.18% XBRL
23 Sep 2020 Robin Pinto Promoter Group Buy Market Purchase 250 116254 0.18% XBRL
07 Sep 2020 Robin Pinto Promoters Buy Market Purchase 500 239705 0.18% XBRL
31 Aug 2020 Robin Pinto Promoter Group Buy Market Purchase 500 250236 0.18% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers GLENMARK.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹2317.90 INR (live) · fetched 2026-08-23 22:31 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
647635.03
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹2,317.90 / (₹1,010,000 / 282,200,000 shares) = ₹2,317.90 / ₹0.00 EPS
FY2025-26 · Annual filing
ROE
0.00%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹1,010,000 / ₹105,121,090,000 = 0.00%
FY2025-26 · Annual filing
Debt/Equity
0.00
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹0 / ₹105,121,090,000 = 0.00
FY2025-26 · Annual filing
Current Ratio
1.77
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹112,997,090,000 / ₹63,764,260,000 = 1.77
FY2025-26 · Annual filing
ROCE
42.42%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹44,595,550,000 / (₹105,121,090,000 + ₹0) = 42.42%
FY2025-26 · Annual filing
Dividend Yield
0.22%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹1,410,340,000 / 282,200,000 shares) / ₹2,317.90 = ₹5.00 / ₹2,317.90
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 9.3%
Net Profit (3y) N/A
Revenue (5y, 3.0y actual) 9.3%
Net Profit (5y) N/A
Revenue (10y, 3.0y actual) 9.3%
Net Profit (10y) N/A

Operating Margin Trend

Expanding

FY2022-23 15.3%
FY2023-24 12.3%
FY2024-25 14.9%
FY2025-26 26.3%

ROCE Trajectory

FY2022-23 14.0%
FY2023-24 16.4%
FY2024-25 17.9%
FY2025-26 42.4%

Earnings Quality

Net profit or operating cash flow was zero or negative in the base or latest year — a growth-rate comparison isn't defined across a sign change.

Sector-Relative Percentile (Healthcare)

ROE 4th
ROCE 98th
Debt/Equity 100th
P/E 0th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹30.63 Bn ₹32.44 Bn ₹34.34 Bn ₹33.88 Bn ₹32.56 Bn ₹32.64 Bn ₹60.47 Bn ₹39.01 Bn ₹37.71 Bn ₹40.18 Bn RevenueFromOperations
Net Profit ₹-12.18 Bn incl. minority ₹-12.14 Bn ₹3.40 Bn ₹3.54 Bn ₹3.48 Bn ₹0.05 Bn incl. minority ₹0.04 Bn ₹0.47 Bn incl. minority ₹0.47 Bn ₹6.10 Bn incl. minority ₹6.10 Bn ₹4.03 Bn incl. minority ₹4.03 Bn ₹-0.00 Bn incl. minority ₹3.01 Bn ₹4.83 Bn incl. minority ₹4.83 Bn ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers GLENMARK.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent1010000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital282200000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets112997090000.0
CurrentLiabilities63764260000.0
EquityAttributableToOwnersOfParent105121090000.0
BorrowingsCurrent + BorrowingsNoncurrent—

My notes